Refine
Has Fulltext
- yes (9)
Is part of the Bibliography
- yes (9)
Document Type
- Journal article (9)
Language
- English (9)
Keywords
- cysteine protease (3)
- rhodesain (3)
- Biologie (2)
- Streptomyces axinellae (2)
- anti-trypanosomal (2)
- drug design (2)
- marine sponge (2)
- prodrug (2)
- protease inhibition (2)
- protease inhibitors (2)
- tetromycin (2)
- 1,4-naphthoquinone (1)
- Meisenheimer complex (1)
- Micromonospora (1)
- actinomycetes (1)
- anti-protease (1)
- antibiotics (1)
- antioxidant (1)
- antiviral agents (1)
- biofilm (1)
- cathepsin (1)
- cathepsin-L (1)
- computational chemistry (1)
- covalent inhibitors (1)
- covalent reversible inhibition (1)
- diazepinomicin (1)
- discovery (1)
- drugs (1)
- electrophilic (het)arene (1)
- in vitro study (1)
- in-vitro (1)
- malaria parasites (1)
- nucleophilic addition (1)
- nucleophilic aromatic substitution (1)
- peptidomimetic sequence (1)
- plakortide E. (1)
- plakortis halichondroides (1)
- protease (1)
- protease inhibitor (1)
- reactivity and selectivity study (1)
- slowly-binding reversible inhibitor (1)
- sortase A (1)
- streptomyces (1)
- structure-activity relationships (1)
- trypanosoma brucei (1)
- warhead (1)
- π-complex (1)
Diazepinomicin is a dibenzodiazepine alkaloid with an unusual structure among the known microbial metabolites discovered so far. Diazepinomicin was isolated from the marine sponge-associated strain Micromonospora sp. RV115 and was identified by spectroscopic analysis and by comparison to literature data. In addition to its interesting preclinical broad-spectrum antitumor potential, we report here new antioxidant and anti-protease activities for this compound. Using the ferric reducing antioxidant power (FRAP) assay, a strong antioxidant potential of diazepinomicin was demonstrated. Moreover, diazepinomicin showed a significant antioxidant and protective capacity from genomic damage induced by the reactive oxygen species hydrogen peroxide in human kidney (HK-2) and human promyelocytic (HL-60) cell lines. Additionally, diazepinomicin inhibited the proteases rhodesain and cathepsin L at an IC50 of 70–90 μM. It also showed antiparasitic activity against trypomastigote forms of Trypanosoma brucei with an IC50 of 13.5 μM. These results showed unprecedented antioxidant and anti-protease activities of diazepinomicin, thus further highlighting its potential as a future drug candidate.